177 related articles for article (PubMed ID: 22530569)
1. Targeting NKG2D in tumor surveillance.
Hayakawa Y
Expert Opin Ther Targets; 2012 Jun; 16(6):587-99. PubMed ID: 22530569
[TBL] [Abstract][Full Text] [Related]
2. NKG2D and cytotoxic effector function in tumor immune surveillance.
Hayakawa Y; Smyth MJ
Semin Immunol; 2006 Jun; 18(3):176-85. PubMed ID: 16675266
[TBL] [Abstract][Full Text] [Related]
3. Innate immune recognition and suppression of tumors.
Hayakawa Y; Smyth MJ
Adv Cancer Res; 2006; 95():293-322. PubMed ID: 16860661
[TBL] [Abstract][Full Text] [Related]
4. Ras activation induces expression of Raet1 family NK receptor ligands.
Liu XV; Ho SS; Tan JJ; Kamran N; Gasser S
J Immunol; 2012 Aug; 189(4):1826-34. PubMed ID: 22798674
[TBL] [Abstract][Full Text] [Related]
5. NKG2D ligands in tumor immunity.
Nausch N; Cerwenka A
Oncogene; 2008 Oct; 27(45):5944-58. PubMed ID: 18836475
[TBL] [Abstract][Full Text] [Related]
6. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity.
Diefenbach A; Hsia JK; Hsiung MY; Raulet DH
Eur J Immunol; 2003 Feb; 33(2):381-91. PubMed ID: 12645935
[TBL] [Abstract][Full Text] [Related]
7. The role of the NKG2D receptor for tumor immunity.
Coudert JD; Held W
Semin Cancer Biol; 2006 Oct; 16(5):333-43. PubMed ID: 16914326
[TBL] [Abstract][Full Text] [Related]
8. Cancer exosomes and NKG2D receptor-ligand interactions: impairing NKG2D-mediated cytotoxicity and anti-tumour immune surveillance.
Mincheva-Nilsson L; Baranov V
Semin Cancer Biol; 2014 Oct; 28():24-30. PubMed ID: 24602822
[TBL] [Abstract][Full Text] [Related]
9. Generation of soluble NKG2D ligands: proteolytic cleavage, exosome secretion and functional implications.
Chitadze G; Bhat J; Lettau M; Janssen O; Kabelitz D
Scand J Immunol; 2013 Aug; 78(2):120-9. PubMed ID: 23679194
[TBL] [Abstract][Full Text] [Related]
10. Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition.
Mamessier E; Sylvain A; Bertucci F; Castellano R; Finetti P; Houvenaeghel G; Charaffe-Jaufret E; Birnbaum D; Moretta A; Olive D
Cancer Res; 2011 Nov; 71(21):6621-32. PubMed ID: 21937679
[TBL] [Abstract][Full Text] [Related]
11. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
[TBL] [Abstract][Full Text] [Related]
12. Cancer immunotherapy using NKG2D and DNAM-1 systems.
Morisaki T; Onishi H; Katano M
Anticancer Res; 2012 Jun; 32(6):2241-7. PubMed ID: 22641658
[TBL] [Abstract][Full Text] [Related]
13. Imbalance of NKG2D and its inhibitory counterparts: how does tumor escape from innate immunity?
Zhang C; Zhang J; Wei H; Tian Z
Int Immunopharmacol; 2005 Jul; 5(7-8):1099-111. PubMed ID: 15914316
[TBL] [Abstract][Full Text] [Related]
14. Natural killer group 2D receptor and its ligands in cancer immune escape.
Duan S; Guo W; Xu Z; He Y; Liang C; Mo Y; Wang Y; Xiong F; Guo C; Li Y; Li X; Li G; Zeng Z; Xiong W; Wang F
Mol Cancer; 2019 Feb; 18(1):29. PubMed ID: 30813924
[TBL] [Abstract][Full Text] [Related]
15. TNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumors.
Maccalli C; Scaramuzza S; Parmiani G
Cancer Immunol Immunother; 2009 May; 58(5):801-8. PubMed ID: 19089424
[TBL] [Abstract][Full Text] [Related]
16. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor.
Zhang T; Barber A; Sentman CL
Cancer Res; 2006 Jun; 66(11):5927-33. PubMed ID: 16740733
[TBL] [Abstract][Full Text] [Related]
17. NKG2D and Related Immunoreceptors.
Strong RK; McFarland BJ
Adv Protein Chem; 2004; 68():281-312. PubMed ID: 15500864
[TBL] [Abstract][Full Text] [Related]
18. Novel role for STAT3 in transcriptional regulation of NK immune cell targeting receptor MICA on cancer cells.
Bedel R; Thiery-Vuillemin A; Grandclement C; Balland J; Remy-Martin JP; Kantelip B; Pallandre JR; Pivot X; Ferrand C; Tiberghien P; Borg C
Cancer Res; 2011 Mar; 71(5):1615-26. PubMed ID: 21257710
[TBL] [Abstract][Full Text] [Related]
19. The NKG2D receptor: sensing stressed cells.
López-Larrea C; Suárez-Alvarez B; López-Soto A; López-Vázquez A; Gonzalez S
Trends Mol Med; 2008 Apr; 14(4):179-89. PubMed ID: 18353724
[TBL] [Abstract][Full Text] [Related]
20. Cytokine-driven regulation of NK cell functions in tumor immunity: role of the MICA-NKG2D system.
Zwirner NW; Fuertes MB; Girart MV; Domaica CI; Rossi LE
Cytokine Growth Factor Rev; 2007; 18(1-2):159-70. PubMed ID: 17324607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
